Related Experiment Video
Updated: Jan 7, 2026

A High-throughput, High-content, Liquid-based C. elegans Pathosystem
Published on: July 1, 2018
Drug Discovery and Repurposing for Coccidioides: A Systematic Review
Sarah Saeger1, Sofia Lozano1, Nathan Wiederhold2
1Department of Molecular Microbiology and Immunology, South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, TX 78249, USA.
None:
Coccidioides immitis and C. posadasii are the causative agents of coccidioidomycosis (CM) or Valley Fever, endemic to the alkaline deserts of North and South America. Clinical treatment of CM is predominantly limited to the triazole and polyene drug classes. There are limited therapeutic options for the treatment of CM, most commonly requiring prolonged courses of therapy with established antifungal agents such as azoles and Amphotericin B, which often lead to toxicity and drug resistance. Clearly, there is a need to develop novel and better antifungal drugs against CM. This review examines both repurposed and recently discovered compounds in various stages of development for the treatment of CM.

